MYM Enters Into Agreement With Engineering Firm to Conduct Environmental Tests for Weedon, QC Project

Cannabis Investing News
Cannabis Investing

MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that it has reached an agreement with BIGIS Expert Conseils of Weedon, QC to conduct environmental tests for the Weedonproject. The initial agreement will see BIGIS Expert Conseils conduct environmental tests for phases one and two of the Weedonproject. The tests will focus on all proposed outbuildings …

MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that it has reached an agreement with BIGIS Expert Conseils of Weedon, QC to conduct environmental tests for the Weedonproject.
The initial agreement will see BIGIS Expert Conseils conduct environmental tests for phases one and two of the Weedonproject. The tests will focus on all proposed outbuildings and greenhouse sites. The tests are expected to conclude Summer 2017.
BIGIS Expert Conseils is a local engineering firm from Weedon, QC. MYM is committed to creating meaningful contacts within the community demonstrated here by partnering with the local engineering company.
To further the goal of creating a lasting relationship within the community of Weedon, MYM has set up quarters in the Weedon Community Centre to better deal with onsite business and community relations until suitable office space is constructed.
Further to local environmental testing and community relations, MYM is on the cusp of beginning a social impact study with regards to the Weedon project.
About MYM
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in CanadaGermany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).
ON BEHALF OF THE BOARD
Rob Gietl
Rob Gietl, CEO
MYM Nutraceuticals Inc.
https://www.mymarijuana.ca
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on https://www.sedar.com .
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States“, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
MYM Investor Relations Contact:
Terry Brown
+1(855)696-2261
Click here to connect with MYM Nutraceuticals Inc (CSE:MYM) to receive an Investor Presentation.

Source: www.prnewswire.com

The Conversation (0)
×